Q32 Bio Inc.
$6.65
▲
4.42%
2026-04-21 09:02:01
www.q32bio.com
NCM: QTTB
Explore Q32 Bio Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$97.29 M
Current Price
$6.65
52W High / Low
$8.04 / $1.34
Stock P/E
3.26
Book Value
$3.27
Dividend Yield
—
ROCE
33.52%
ROE
1.25%
Face Value
—
EPS
$2.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
24
Beta
-1.02
Debt / Equity
36.52
Current Ratio
4.85
Quick Ratio
4.85
Forward P/E
-0.94
Price / Sales
1.37
Enterprise Value
$40.93 M
EV / EBITDA
2.37
EV / Revenue
0.76
Rating
None
Target Price
$14.33
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Voyager Therapeutics, Inc. | $4.23 | — | $252.11 M | — | -58.41% | -48.29% | $5.55 / $2.65 | $3.32 |
| 2. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
| 3. | LeonaBio, Inc. | $9.38 | — | $83.23 M | — | -76.55% | -2.91% | $14.21 / $2.2 | $5.2 |
| 4. | CAMP4 THERAPEUTICS CORPORATION | $4.51 | — | $233.12 M | — | -50.89% | -1.45% | $7.75 / $1.3 | $0.92 |
| 5. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 6. | Tenaya Therapeutics, Inc. | $0.74 | — | $169.71 M | — | -70.98% | -83.84% | $2.35 / $0.36 | $0.57 |
| 7. | Connect Biopharma Holdings Limited | $2.68 | — | $158.82 M | — | -24.19% | -82.72% | $3.82 / $0.65 | $0.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 53.74 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | 45.88 M | -7.58 M | -9.17 M | -12.23 M | -14.53 M | — |
| Net Profit | 57.73 M | -7.39 M | -9.49 M | -11.03 M | -14.19 M | — |
| EPS in Rs | 3.95 | -0.51 | -0.65 | -0.75 | -0.97 | -1.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 53.74 M | 0 M | -6.65 M | 6.65 M |
| Operating Profit | 16.9 M | -66.1 M | -48.26 M | -39.23 M |
| Net Profit | 29.82 M | -47.73 M | -53.74 M | -42.81 M |
| EPS in Rs | 2.04 | -3.26 | -3.67 | -2.93 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.78 M | 92.33 M | 47.06 M | 61.77 M |
| Total Liabilities | 19.76 M | 86.66 M | 229.98 M | 192.49 M |
| Equity | 42.01 M | 5.67 M | -182.92 M | -130.71 M |
| Current Assets | 55.05 M | 81.88 M | 28.72 M | 46.85 M |
| Current Liabilities | 11.35 M | 16.46 M | 14.11 M | 57.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -33.54 M | -67.72 M | -18.68 M | -10.96 M |
| Investing CF | 7 M | 19.93 M | -0.01 M | -2.47 M |
| Financing CF | -3.12 M | 95.14 M | 0.41 M | 30.07 M |
| Free CF | -33.54 M | -67.79 M | -18.68 M | -13.44 M |
| Capex | — | -0.07 M | -0.01 M | -2.48 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 100% | -200% | — | — |
| Earnings Growth % | 11.18% | -25.54% | — | — |
| Profit Margin % | — | 808.04% | -643.65% | — |
| Operating Margin % | — | 725.53% | -589.76% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | 718.03% | -584.2% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-03-26 | 1:0.0555556 |